{"id":5115,"date":"2025-11-04T21:28:58","date_gmt":"2025-11-04T18:28:58","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5115"},"modified":"2025-11-05T00:18:00","modified_gmt":"2025-11-04T21:18:00","slug":"sarepta-dmd-exon-skipping-therapies-fail-confirmatory-study-stock-price-down","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/sarepta-dmd-exon-skipping-therapies-fail-confirmatory-study-stock-price-down\/","title":{"rendered":"Les th\u00e9rapies de Sarepta ciblant le saut d&#039;exons dans la dystrophie musculaire de Duchenne (DMD) \u00e9chouent \u00e0 une \u00e9tude de confirmation, le cours de l&#039;action chute."},"content":{"rendered":"<p class=\"wp-block-paragraph\">Les difficult\u00e9s li\u00e9es \u00e0 la mutation Sarepta Therapeutics ne font que s&#039;aggraver. Chez les patients atteints de dystrophie musculaire de Duchenne, l&#039;entreprise a constat\u00e9 que ses traitements par saut d&#039;exon, Vyondys 53 et Amondys 45, n&#039;am\u00e9lioraient pas significativement la fonction motrice. <a href=\"https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-third-quarter-2025-financial\" target=\"_blank\" rel=\"noreferrer noopener\">Annonce de Sarepta<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les \u00e9changes avant l&#039;ouverture du march\u00e9 mardi ont vu le titre de biotech se vendre \u00e0 $15,60, soit une baisse de 36% par rapport au cours de cl\u00f4ture de lundi de $24,45.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dans une lettre adress\u00e9e \u00e0 leurs clients mardi matin, les analystes de William Blair ont indiqu\u00e9 que les r\u00e9sultats des essais cliniques de ces m\u00e9dicaments jetaient un doute sur leur avenir, malgr\u00e9 l&#039;optimisme de Sarepta. Ils ont ajout\u00e9\u00a0: \u2019\u00a0Nous consid\u00e9rons l&#039;incapacit\u00e9 de l&#039;essai ESSENCE \u00e0 atteindre son objectif principal comme un \u00e9l\u00e9ment n\u00e9gatif.\u00a0\u201c<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bien que la direction soit certaine que Vyondys 53 et Amondys 45 ne perdront pas leur autorisation de mise sur le march\u00e9 \u00e0 ce titre, nous restons sceptiques et pensons que la r\u00e9action du titre (en baisse de 37% apr\u00e8s la cl\u00f4ture) indique que les investisseurs sont \u00e9galement inquiets quant \u00e0 l&#039;avenir de ces deux m\u00e9dicaments.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Suivre cette page<\/strong>&nbsp;&gt;&gt;&gt;&nbsp;<a href=\"https:\/\/dmdwarrior.com\/fr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Tous les essais cliniques pour la dystrophie musculaire de Duchenne<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Sarepta Therapeutics&#8217; difficulties only get worse. In patients with Duchenne muscular dystrophy, the business found that their exon-skipping treatments, Vyondys 53 and Amondys 45, did not considerably enhance motor function. >>> Sarepta Announcement Tuesday&#8217;s pre-market trading saw the biotech selling at $15.60, a 36% decrease from Monday&#8217;s closing share price of $24.45. William Blair analysts [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5117,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[453,77,178,65,394],"class_list":["post-5115","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-amondys-45","tag-exon-skipping","tag-exon-skipping-therapies","tag-sarepta","tag-vyondys-53"],"subtitle":"Selon Sarepta, les patients atteints de dystrophie musculaire de Duchenne n'ont pas constat\u00e9 d'am\u00e9lioration substantielle de leur fonction motrice avec leurs th\u00e9rapies d'exclusion d'exons, Vyondys 53 et Amondys 45.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/5115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=5115"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/5115\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/5117"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=5115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=5115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=5115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}